Expression of human IL-1α after intramarrow gene transfer into healthy non-human primate by adenoviral vector

Journal of Medical Primatology

Volumn 34, Issue 1, 2005, Pages 1-12

  Bécard, Nicolas ^a   de Revel, Thierry ^a,b   Sorg, Tania ^c   Dormont, Dominique ^a   Le Grand, Roger ^a  

^a INSTITUT DE RADIOPROTECTION ET DE SÛRETÉ NUCLÉAIRE   (France)

^b PERCY MILITARY HOSPITAL   (France)

^c TRANSGENE S A   (France)

Author keywords

Adenoviral vector; Bone marrow; Gene transfer; Hematopoiesis; Interleukin 1 ; Macaque

Indexed keywords

ADENOVIRUS VECTOR; C REACTIVE PROTEIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BONE MARROW; CONTROLLED STUDY; CYTOKINE PRODUCTION; DNA VECTOR; GENE EXPRESSION; GENE TRANSFER; LEUKOCYTE COUNT; MACACA; MALE; MONOCYTE; MYELOPOIESIS; NEUTROPHIL; NONHUMAN; PRIMATE; PRIORITY JOURNAL; THROMBOCYTE COUNT; TRANSGENE; VIRAL GENE THERAPY;

ADENOVIRIDAE; ANIMALS; BONE MARROW CELLS; C-REACTIVE PROTEIN; DNA PRIMERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HEMATOPOIETIC STEM CELLS; HUMANS; INTERLEUKIN-1; MACACA FASCICULARIS; MALE; MAURITIUS; NUCLEIC ACID AMPLIFICATION TECHNIQUES; TRANSGENES;

EID: 12744269588     PISSN: 00472565     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0684.2004.00085.x     Document Type: Article

References (58)

1. Bartelmez SH, Stanley ER: Synergism between hemopoietic growth factors (HGFs) detected by their effects on cells bearing receptors for a lineage specific HGF: assay of hemopoietin-1. J Cell Physiol 122:370-378, 1985.
2. Benjamin WR, Tare NS, Hayes TJ, Becker JM, Anderson TD: Regulation of hemopoiesis in myelosuppressed mice by human recombinant IL-1 alpha. J Immunol 142:792-799, 1989.
3. Benveniste O, Vaslin B, Villinger F, Le Grand R, Ansari AA, Dormont D: Cytokine mRNA levels in unmanipulated (ex vivo) and in vitro stimulated monkey PBMCs using a semi-quantitative RT-PCR and high sensitivity fluorescence-based detection strategy. Cytokine 8:32-41, 1996.
4. Cavazzana-Calvo M, Hacein-Bey S, de Saint Basile G, Gross F, Yvon E, Nusbaum P, Selz F, Hue C, Certain S, Casanova JL, Bousso P, Deist FL, Fischer A: Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 288:669-672, 2000.
5. Chartier C, Degryse E, Gantzer M, Dieterle A, Pavirani A, Mehtali M: Efficient generation of recombinant adenovirus vectors by homologous recombination in Escherichia coli. J Virol 70:4805-4810, 1996.
6. Chuah MK, Brems H, Vanslembrouck V, Collen D, Vandendriessche T: Bone marrow stromal cells as targets for gene therapy of hemophilia A. Hum Gene Ther 9:353-365, 1998.
7. De Revel T, Becard N, Sorg T, Rousseau S, Spano JP, Thiebot H, Methali M, Gras G, Le Grand R, Dormont D: Retroviral interleukin 1alpha gene transfer in bone marrow stromal cells in a primate model: induction of myelopoiesis stimulation. Br J Haematol 118:875-884, 2002.
8. Deans RJ, Moseley AB: Mesenchymal stem cells: biology and potential clinical uses. Exp Hematol 28:875-884, 2000.
9. Demetri GD: Pharmacologic treatment options in patients with thrombocytopenia. Semin Hematol 37:11-18, 2000.
10. Dinarello CA: Biologic basis for interleukin-1 in disease. Blood 87:2095-2147, 1996.
11. Donahue RE, Dunbar CE: Update on the use of non-human primate models for preclinical testing of gene therapy approaches targeting hematopoietic cells. Hum Gene Ther 12:607-617, 2001.
12. Dubois CM, Ruscetti FW, Keller JR, Oppenheim JJ, Hestdal K, Chizzonite R, Neta R: In vivo interleukin-1 (IL-1) administration indirectly promotes type II IL-1 receptor expression on hematopoietic bone marrow cells: novel mechanism for the hematopoietic effects of IL-1. Blood 78:2841-2847, 1991.
13. Duff GW: Cytokines and acute phase proteins in rheumatoid arthritis. Scand J Rheumatol Suppl 100:9-19, 1994.
14. Dunbar CE, Seidel NE, Doren S, Sellers S, Cline AP, Metzger ME, Agricola BA, Donahue RE, Bodine DM: Improved retroviral gene transfer into murine and Rhesus peripheral blood or bone marrow repopulating cells primed in vivo with stem cell factor and granulocyte colony-stimulating factor. Proc Natl Acad Sci USA 93:11871-11876, 1996.
15. Eisenberg SP, Evans RJ, Arend WP, Verderber E, Brewer MT, Hannum CH, Thompson RC: Primary structure and functional expression from complementary DNA of a human interleukin-1 receptor antagonist. Nature 343:341-346, 1990.
16. Fang B, Eisensmith RC, Li XH, Finegold MJ, Shedlovsky A, Dove W, Woo SL: Gene therapy for phenylketonuria: phenotypic correction in a genetically deficient mouse model by adenovirus-mediated hepatic gene transfer. Gene Ther 1:247-254, 1994.
17. Foley R, Ellis R, Walker I, Wan Y, Carter R, Boyle M, Braciak T, Addison C, Graham F, Gauldie J: Intramarrow cytokine gene transfer by adenoviral vectors in dogs. Hum Gene Ther 8:545-553, 1997.
18. Gabay C, Gay-Croisier F, Roux-Lombard P, Meyer O, Maineti C, Guerne PA, Vischer T, Dayer JM: Elevated serum levels of interleukin-1 receptor antagonist in polymyositis/dermatomyositis. A biologic marker of disease activity with a possible role in the lack of acute-phase protein response. Arthritis Rheum 37:1744-1751, 1994.
19. Gahery-Segard H, Molinier-Frenkel V, Le Boulaire C, Saulnier P, Opolon P, Lengagne R, Gautier E, Le Cesne A, Zitvogel L, Venet A, Schatz C, Courtney M, Le Chevalier T, Tursz T, Guillet JG, Farace F: Phase I trial of recombinant adenovirus gene transfer in lung cancer. Longitudinal study of the immune responses to transgene and viral products. J Clin Invest 100:2218-2226, 1997.
20. Gasparetto C, Laver J, Abboud M, Gillio A, Smith C, O'Reilly RJ, Moore MA: Effects of interleukin-1 on hematopoietic progenitors: evidence of stimulatory and inhibitory activities in a primate model. Blood 74:547-550, 1989.
21. Haskill S, Martin G, Van Le L, Morris J, Peace A, Bigler CF, Jaffe GJ, Hammerberg C, Sporn SA, Fong S, Arend WP, Ralph P: cDNA cloning of an intracellular form of the human interleukin 1 receptor antagonist associated with epithelium. Proc Natl Acad Sci USA 88:3681-3685, 1991.
22. Hurwitz DR, Kirchgesser M, Merrill W, Galanopoulos T, McGrath CA, Emami S, Hansen M, Cherington V, Appel JM, Bizinkauskas CB, Brackmann HH, Levine PH, Greenberger JS: Systemic delivery of human growth hormone or human factor IX in dogs by reintroduced genetically modified autologous bone marrow stromal cells. Hum Gene Ther 8:137-156, 1997.
23. Janik JE, Miller LL, Longo DL, Powers GC, Urba WJ, Kopp WC, Gause BL, Curti BD, Fenton RG, Oppenheim JJ, Conlon KC, Holmlund JT, Sznol M, Sharfman WH, Steis RG, Creekmore SP, Alvord WG, Beauchamp AE, Smith JW, II: Phase II trial of interleukin 1 alpha and indomethacin in treatment of metastatic melanoma. J Natl Cancer Inst 88:44-49, 1996.
24. Jensen LE, Muzio M, Mantovani A, Whitehead AS: IL-1 signaling cascade in liver cells and the involvement of a soluble form of the IL-1 receptor accessory protein. J Immunol 164:5277-5286, 2000.
25. Johnson CS, Keckler DJ, Topper MI, Braunschweiger PG, Furmanski P: In vivo hematopoietic effects of recombinant interleukin-1 alpha in mice: stimulation of granulocytic, monocytic, megakaryocytic, and early erythroid progenitors, suppression of late-stage erythropoiesis, and reversal of erythroid suppression with erythropoietin. Blood 73:678-683, 1989.
26. Liou LB: Serum and in vitro production of IL-1 receptor antagonist correlate with C-reactive protein levels in newly diagnosed, untreated lupus patients. Clin Exp Rheumatol 19:515-523, 2001.
27. Lusky M, Christ M, Rittner K, Dieterle A, Dreyer D. Mourot B, Schultz H, Stoeckel F, Pavirani A, Mehtali M: In vitro and in vivo biology of recombinant adenovirus vectors with E1, E1/E2A, or E1/E4 deleted. J Virol 72:2022-2032, 1998.
28. Lutzko C, Dube ID, Stewart AK: Recent progress in gene transfer into hematopoietic stem cells. Crit Rev Oncol Hematol 30:143-158, 1999.
29. MacVittie TJ, Farese AM, Patchen ML, Myers LA: Therapeutic efficacy of recombinant interleukin-6 (IL-6) alone and combined with recombinant human IL-3 in a nonhuman primate model of high-dose, sublethal radiation-induced marrow aplasia. Blood 84:2515-2522, 1994.
30. Marley S, Reilly I, Russell N: Interleukin 1 has positive and negative regulatory effects in human long-term bone marrow culture. Exp Hematol 20:75-79, 1992.
31. Means RT, Jr, Dessypris EN, Krantz SB: Inhibition of human erythroid colony-forming units by interleukin-1 is mediated by gamma interferon. J Cell Physiol 150:59-64, 1992.
32. Mochizuki DY, Eisenman JR, Conlon PJ, Larsen AD, Tushinski RJ: Interleukin 1 regulates hematopoietic activity, a role previously ascribed to hemopoietin 1. Proc Natl Acad Sci USA 84:5267-5271, 1987.
33. Monroy RL, Skelly RR, Davis TA, MacVittie TJ: Therapeutic evaluation of interleukin-1 for stimulation of hematopoiesis in primates after autologous bone marrow transplantation. Biotherapy 4:97-108, 1992.
34. Neta R: Modulation with cytokines of radiation injury: suggested mechanisms of action. Environ Health Perspect 105 (Suppl 6):1463-1465, 1997.
35. Neta R, Sztein MB, Oppenheim JJ, Gillis S, Douches SD: The in vivo effects of interleukin 1. I. Bone marrow cells are induced to cycle after administration of interleukin 1. J Immunol 139:1861-1866, 1987.
36. Nunes FA, Furth EE, Wilson JM, Raper SE: Gene transfer into the liver of nonhuman primates with E1-deleted recombinant adenoviral vectors: safety of readministration. Hum Gene Ther 10:2515-2526, 1999.
37. Richards CD, Braciak T, Xing Z, Graham F, Gauldie J: Adenovirus vectors for cytokine gene expression. Ann N Y Acad Sci 762:282-292; discussion 292-293, 1995.
38. Rosenfeld MA, Yoshimura K, Trapnell BC, Yoneyama K, Rosenthal ER, Dalemans W, Fukayama M, Bargon J, Stier LE, Stratford-Perricaudet L et al: In vivo transfer of the human cystic fibrosis transmembrane conductance regulator gene to the airway epithelium. Cell 68:143-155, 1992.
39. Roth-Isigkeit A, Borstel TV, Seyfarth M, Schmucker P: Perioperative serum levels of tumour-necrosis-factor alpha (TNF-alpha), IL-1 beta, IL-6, IL-10 and soluble IL-2 receptor in patients undergoing cardiac surgery with cardiopulmonary bypass without and with correction for haemodilution. Clin Exp Immunol 118:242-246, 1999.
40. Sambrook J, Fritsch E, Maniatis T: Molecular Cloning: a Laboratory Manual. New York: Cold Spring Harbor Laboratory Press, Inc., 1989.
41. Schwertschlag US, Trepicchio WL, Dykstra KH, Keith JC, Turner KJ, Dorner AJ: Hematopoietic, immunomodulatory and epithelial effects of interleukin-11. Leukemia 13:1307-1315, 1999.
42. Shi PA, Hematti P, Von Kalle C, Dunbar CE: Genetic marking as an approach to studying in vivo hematopoiesis: progress in the non-human primate model. Oncogene 21:3274-3283, 2002.
43. Smith DE, Hanna R, Della F, Moore H, Chen H, Farese AM, MacVittie TJ, Virca GD, Sims JE: The soluble form of IL-1 receptor accessory protein enhances the ability of soluble type II IL-1 receptor to inhibit IL-1 action. Immunity 18:87-96, 2003.
44. Smith JW, II, Urba WJ, Curti BD, Elwood LJ, Steis RG, Janik JE, Sharfman WH, Miller LL, Fenton RG, Conlon KC et al: The toxic and hematologic effects of interleukin-1 alpha administered in a phase I trial to patients with advanced malignancies. J Clin Oncol 10:1141-1152, 1992.
45. Smith TA, Mehaffey MG, Kayda DB, Saunders JM, Yei S, Trapnell BC, McClelland A, Kaleko M: Adenovirus mediated expression of therapeutic plasma levels of human factor IX in mice. Nat Genet 5:397-402, 1993.
46. Stork L, Barczuk L, Kissinger M, Robinson W: Interleukin-1 accelerates murine granulocyte recovery following treatment with cyclophosphamide. Blood 73:938-944, 1989.
47. Stork LC, Peterson VM, Rundus CH, Robinson WA: Interleukin-1 enhances murine granulopoiesis in vivo. Exp Hematol 16:163-167, 1988.
48. Takahara Y, Hamada K, Okano A, Takagi T, Shimotono K: Gene-transfer into bone marrow cells. Hum Cell 4:18-24, 1991.
49. Tanikawa S, Nakao I, Tsuneoka K, Nara N: Effects of recombinant granulocyte colony-stimulating factor (rG-CSF) and recombinant granulocyte-macrophage colony-stimulating factor (rGM-CSF) on acute radiation hematopoietic injury in mice. Exp Hematol 17:883-888, 1989.
50. Tewari A, Buhles WC, Jr, Starnes HF, Jr: Preliminary report: effects of interleukin-1 on platelet counts. Lancet 336:712-714, 1990.
51. Ulich TR, del Castillo J, Keys M, Granger GA, Ni RX: Kinetics and mechanisms of recombinant human interleukin 1 and tumor necrosis factor-alpha-induced changes in circulating numbers of neutrophils and lymphocytes. J Immunol 139:3406-3415, 1987.
52. Veldhuis GJ, Willemse PH, Mulder NH, Limburg PC, De Vries EG: Potential use of recombinant human interleukin-6 in clinical oncology. Leuk Lymphoma 20:373-379, 1996.
53. Villinger F, Brar SS, Mayne A, Chikkala I, Ansari AA: Comparative sequence analysis of cytokine genes from human and nonhuman primates. J Immunol 155:3946-3954, 1995.
54. Vogel SN, Douches SD, Kaufman EN, Neta R: Induction of colony stimulating factor in vivo by recombinant interleukin 1 alpha and recombinant tumor necrosis factor alpha 1. J Immunol 138:2143-2148, 1987.
55. Wagner TL, Horton VL, Carlson GL, Myhre PE, Gibson SJ, Imbertson LM, Tomai MA: Induction of cytokines in cynomolgus monkeys by the immune response modifiers, imiquimod, S-27609 and S-28463. Cytokine 9:837-845, 1997.
56. Warren MK, Conroy LB, Rose JS: The role of interleukin 6 and interleukin 1 in megakaryocyte development. Exp Hematol 17:1095-1099, 1989.
57. Weinstein JA, Taylor JM: Interleukin-1 and the acute-phase response: induction of mouse liver serum amyloid A mRNA by murine recombinant interleukin-1. J Trauma 27:1227-1232, 1987.
58. Yang M, Li K, Chui CM, Yuen PM, Chan PK, Chuen CK, Li CK, Fok TF: Expression of interleukin (IL) 1 type I and type II receptors in megakaryocytic cells and enhancing effects of IL-1beta on megakaryocytopoiesis and NF-E2 expression. Br J Haematol 111:371-380, 2000.